Novartis India Limited (NOVARTIND.BO)
INR 770.7
(-1.19%)
INR 770.7
(-1.19%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.24 Billion INR | -5.9% |
| 2022 | 9.82 Billion INR | 2.65% |
| 2021 | 9.57 Billion INR | -4.46% |
| 2020 | 10.02 Billion INR | -6.99% |
| 2019 | 10.77 Billion INR | 9.69% |
| 2018 | 9.82 Billion INR | -11.53% |
| 2017 | 11.1 Billion INR | -3.43% |
| 2016 | 11.49 Billion INR | -19.73% |
| 2015 | 14.32 Billion INR | 15.64% |
| 2014 | 12.38 Billion INR | 3.05% |
| 2013 | 12.02 Billion INR | 5.34% |
| 2012 | 11.41 Billion INR | 10.4% |
| 2011 | 10.33 Billion INR | 15.73% |
| 2010 | 8.93 Billion INR | 17.44% |
| 2009 | 7.6 Billion INR | 13.63% |
| 2008 | 6.69 Billion INR | 14.93% |
| 2007 | 5.82 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 8.9 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 8.7 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 9.24 Billion INR | 0.0% |
| 2023 FY | 9.24 Billion INR | -5.9% |
| 2022 Q2 | 9.97 Billion INR | 0.0% |
| 2022 FY | 9.82 Billion INR | 2.65% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 9.82 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 9.57 Billion INR | 0.0% |
| 2021 Q2 | 9.72 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 9.57 Billion INR | -4.46% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 10.02 Billion INR | -6.99% |
| 2020 Q2 | 10.29 Billion INR | 0.0% |
| 2020 Q4 | 10.02 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 10.77 Billion INR | 9.69% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 10.94 Billion INR | 0.0% |
| 2019 Q4 | 10.77 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 10.15 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 9.82 Billion INR | -11.53% |
| 2018 Q4 | 9.82 Billion INR | 0.0% |
| 2017 Q4 | 11.1 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 FY | 11.1 Billion INR | -3.43% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 11.84 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 11.49 Billion INR | 0.0% |
| 2016 Q2 | 11.42 Billion INR | 0.0% |
| 2016 FY | 11.49 Billion INR | -19.73% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 14.32 Billion INR | 0.0% |
| 2015 FY | 14.32 Billion INR | 15.64% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 13.42 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 12.38 Billion INR | 3.05% |
| 2014 Q4 | 12.38 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 12.07 Billion INR | 0.0% |
| 2013 Q2 | 11.48 Billion INR | 0.0% |
| 2013 Q4 | 12.02 Billion INR | 0.0% |
| 2013 FY | 12.02 Billion INR | 5.34% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 FY | 11.41 Billion INR | 10.4% |
| 2012 Q4 | 11.41 Billion INR | 0.0% |
| 2012 Q2 | 10.42 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 10.33 Billion INR | 0.0% |
| 2011 FY | 10.33 Billion INR | 15.73% |
| 2010 FY | 8.93 Billion INR | 17.44% |
| 2009 FY | 7.6 Billion INR | 13.63% |
| 2008 FY | 6.69 Billion INR | 14.93% |
| 2007 FY | 5.82 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bal Pharma Limited | 3.2 Billion INR | -188.69% |
| Achyut Healthcare Limited | 309.52 Million INR | -2888.253% |
| Alkem Laboratories Limited | 155.74 Billion INR | 94.061% |
| Divi's Laboratories Limited | 154.7 Billion INR | 94.021% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 93.558% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 67.551% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -419.114% |
| Mankind Pharma Limited | 119.63 Billion INR | 92.269% |
| Medicamen Biotech Limited | 2.94 Billion INR | -214.044% |
| Medico Remedies Limited | 961.95 Million INR | -861.513% |
| Megasoft Limited | 3.65 Billion INR | -152.782% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -16.437% |
| Piramal Pharma Limited | 153.11 Billion INR | 93.959% |
| Sequent Scientific Limited | 15.4 Billion INR | 39.955% |
| Sigachi Industries Limited | 6.94 Billion INR | -33.245% |
| Ajanta Pharma Limited | 46.38 Billion INR | 80.059% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 98.918% |
| Brooks Laboratories Limited | 904.45 Million INR | -922.639% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 64.179% |
| Themis Medicare Limited | 5.66 Billion INR | -63.295% |
| Unichem Laboratories Limited | 31.69 Billion INR | 70.816% |
| Hester Biosciences Limited | 6.62 Billion INR | -39.644% |
| Venus Remedies Limited | 6.26 Billion INR | -47.557% |
| Indoco Remedies Limited | 21.44 Billion INR | 56.874% |
| Ind-Swift Limited | 6.54 Billion INR | -41.325% |
| Aarti Drugs Limited | 24.32 Billion INR | 61.974% |
| Alpa Laboratories Limited | 1.82 Billion INR | -406.473% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 14.202% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 97.613% |
| Granules India Limited | 55.2 Billion INR | 83.247% |
| Gufic Biosciences Limited | 10.92 Billion INR | 15.341% |
| Hikal Limited | 24.87 Billion INR | 62.812% |
| RPG Life Sciences Limited | 5.12 Billion INR | -80.344% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 58.967% |
| Windlas Biotech Limited | 6.26 Billion INR | -47.704% |
| ZIM Laboratories Limited | 4.46 Billion INR | -107.002% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 20.614% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 58.789% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 91.991% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 97.948% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -20.886% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1864.48% |
| Ipca Laboratories Limited | 111.01 Billion INR | 91.668% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -513.07% |
| Laurus Labs Limited | 83.87 Billion INR | 88.972% |
| NATCO Pharma Limited | 69.06 Billion INR | 86.607% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 57.786% |
| Shilpa Medicare Limited | 30.93 Billion INR | 70.098% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 60.657% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 93.859% |
| Wanbury Limited | 3.43 Billion INR | -169.272% |
| Wockhardt Limited | 76.49 Billion INR | 87.908% |
| Strides Pharma Science Limited | 58.39 Billion INR | 84.161% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 23.803% |
| Suven Life Sciences Limited | 2.84 Billion INR | -224.648% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -152.113% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 85.65% |
| Eris Lifesciences Limited | 70.48 Billion INR | 86.878% |
| Lupin Limited | 239.97 Billion INR | 96.146% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -79.584% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -128.567% |
| Valiant Laboratories Limited | 3.42 Billion INR | -169.905% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 96.841% |
| FDC Limited | 24.68 Billion INR | 62.524% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 76.843% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -326.082% |
| Neuland Laboratories Limited | 18.32 Billion INR | 49.528% |
| Morepen Laboratories Limited | 12.93 Billion INR | 28.478% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -285.289% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -177.403% |